STOCK TITAN
  1. Home
  2. News
  3. VOR

Vor Bio to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Piper Sandler 34th Annual Healthcare Conference
Presentation: Tuesday, November 29, 2022 at 9:30 am ET
Location: Lotte New York Palace Hotel, New York, NY

5th Annual Evercore ISI HealthCONx Virtual Conference
Fireside chat: Thursday, December 1 at 3:05 pm ET

The JMP Securities Hematology and Oncology Virtual Summit
Fireside chat: Tuesday, December 6, 2022 at 1:20 pm ET

A live webcast and archived replay of the presentation and fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com

 


Stock VOR logo
Vor Biopharma Inc

NASDAQ:VOR

VOR Rankings

#4146 Ranked by Market Cap
#4827 Ranked by Stock Gains
N/A Ranked by Dividends

VOR Latest News

Apr 1, 2024
Vor Bio to Participate in Upcoming Investor Conferences
Mar 20, 2024
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Mar 5, 2024
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 4, 2024
Vor Bio to Participate in Upcoming Investor Conferences
Feb 7, 2024
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

VOR Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About VOR

vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar